Oncology

Summit Therapeutics Refocuses on Oncology Drug

Cardiff Oncology pipeline update: onvansertib trials, FDA meeting, and catalysts

Cardiff Oncology is a clinical-stage biotechnology company advancing a PLK1 inhibitor across multiple oncology trials. This plan centers on onvansertib, recent FDA-related disclosure, and the company’s documented trial catalysts.

HPN328 Merck: Harpoon deal deepens oncology

Merck has completed its acquisition of Harpoon Therapeutics, adding an immuno-oncology company to its pipeline as it keeps building beyond Keytruda. For analysts and BD teams, the deal is a signal to watch for follow-on M&A and pipeline diversification.

5 Notable Oncology FDA Approvals Granted in May: A B2B Analysis

In May 2026, the FDA granted five major oncology approvals, including a first-in-class combination for non-muscle invasive bladder cancer. This analysis covers the approvals, their competitive impact, and next milestones for pharma teams.

May 2026 FDA Oncology Actions: 8 Approvals Reshape the Landscape

In May 2026, the FDA issued 8 oncology and hematology approvals, including durvalumab for high-risk non-muscle invasive bladder cancer. This analysis covers the approvals, their competitive impact, and what to watch next in FDA oncology guidance.

Pfizer sharpens prostate cancer case with Talzenna win — oncology

Pfizer announced a Phase III win for Talzenna (talazoparib) plus Xtandi (enzalutamide) in metastatic castration-sensitive prostate cancer, setting up a potential broader label. This analysis covers the TALAPRO-3 results, implications for the prostate cancer treatment landscape, and key milestones for pharma teams and investors.

China’s Rise in Drug Development Looms Over U.S. Oncology Market

Structured plan for China’s Rise in Drug Development Looms Over U.S. Oncology Market

A Brief History of Major Events in Oncology

Structured plan for A Brief History of Major Events in Oncology